Biopsychosocial Pain Medicine: Integrating Psychiatric and Behavioral Therapies into Medical Treatment

Successful management of chronic pain disorders and diseases starts with an appreciation of the many biological and psychosocial factors, including pain generators and comorbidities, that may affect outcome. Choosing the appropriate treatment for any one patient hinges on a careful assessment of these factors and a reasoned and feasible outcomes-oriented treatment plan that controls as much of the variance as possible. Chronic pain, a coping challenge for everyone, causes some psychosocial problems for everyone and clinically significant psychiatric disorder in many. Or, chronic pain onset can worsen preexisting psychosocial problems and psychiatric disorders. Simple screening questions are highly sensitive, missing few cases. Specific diagnosis requires a more detailed interview. Suicide is the most common mortal complication of chronic pain, particularly with comorbid depression, and should be asked about routinely. Depression, anxiety disorders, and substance abuse are the most common complicating psychiatric comorbidities. These should be identified and managed to achieve optimal surgical outcomes. A plethora of effective medications, some for specific depression and anxiety disorder diagnoses, are available. Substance abuse and addiction are more difficult and may require special treatments. Skillfully treating both pain and psychiatric comorbidity leads to the best functional outcomes for the person in pain.

KEYWORDS

Anxiety - depression - pain - pharmacology - biopsychosocial

REFERENCES

• 1 Gallagher R M. Primary care and pain medicine. A community solution to the public health problem of chronic pain.  Med Clin North Am. 1999;  83 555-583
• 2 Gallagher R M. The pain medicine and primary care community rehabilitation model: monitored care for pain disorders in multiple settings.  Clin J Pain. 1999;  15(1) 1-3
• 3 Rome H, Rome J. Limbically augmented pain syndrome (LAPS): kindling, corticolimbic sensitization, and convergence of affective and sensory symptoms in chronic pain disorders.  Pain Med. 2000;  1 7-23
• 4 Carr D, Aronoff G. The future of pain management. In: Aronoff, GM Evaluation and Treatment of Chronic Pain. Baltimore; Williams & Wilkins 1999: 691-707
• 5 Flor H. The functional organization of the brain in chronic pain.  Prog Brain Res. 2000;  129 313-322
• 6 Price D D. Psychological and neural mechanisms of the affective dimension of pain.  Science. 2000;  288 1769-1772
• 7 Gallagher R M, Woznicki M. Low back pain rehabilitation. In: Stoudemire A, Fogel BS Medical-Psychiatric Practice. 2nd ed. Arlington, VA; American Psychiatric Publishing 1993: 227-252
• 8 Marbach J J, Lennon M C, Link B G, Dohrenwend B P. Losing face: sources of stigma as perceived by chronic facial pain patients.  J Behav Med. 1990;  13 583-604
• 9 Marbach J J, Lennon M C, Link B G. Losing face, sources of stigma as perceived by chronic facial pain patients.  J Behav Med. 1990;  13 583-604
• 10 Dohrenwend B, Marbach J, Raphael K, Gallagher R M. Why is depression co-morbid with chronic facial pain? A family study test of alternative hypotheses.  Pain. 1999;  83 183-192
• 11 Jensen M, Brant-Zawadzki M N, Obuchowski N et al.. Magnetic resonance imaging of the lumbar spine in people without back pain.  N Engl J Med. 1994;  331 69-73
• 12 Deyo R A, Phillips W R. Low back pain: a primary care challenge.  Spine. 1996;  21 2826-2832
• 13 Rosomoff H, Steele-Rosomoff R. Low back pain. Evaluation and management in the primary care setting.  Med Clin North Am. 1999;  83 643-662
• 14 Moseley J B, O'Malley K, Petersen N J et al.. A controlled trial of arthroscopic surgery for osteoarthritis of the knee.  N Engl J Med. 2002;  347 81-88
• 15 Gallagher R M. Treatment planning in pain medicine. Integrating medical, physical, and behavioral therapies.  Med Clin North Am. 1999;  83 823-849
• 16 Gallagher R M, Myers P. Referral delay in back pain patients on worker's compensation: costs and policy implications.  Psychosomatics. 1996;  37 270-284
• 17 Cutler R, Fishbain D A, Rosomoff H L et al.. Does non-surgical pain center treatment of chronic pain return patients to work? A review and meta-analysis of the literature.  Spine. 1994;  19 643-652
• 18 Haddox J D. Appropriate use of the chronic pain specialist and the role of conceptual fluidity. In: Cohen M, Campbell J Pain Treatment at a Crossroads: A Practical and Conceptual Reappraisal. Progress in Pain Research and Management, Vol 7. Seattle; IASP Press 1996: 297-306
• 19 Gallagher R M, Verma S. Managing pain and co-morbid depression: a public health challenge.  Semin Clin Neuropsychiatry. 1999;  4 203-220
• 20 California Assembly Bill No. 791 .1999
• 21 Cano A, Weisberg J, Gallagher R M. Marital satisfaction and pain severity mediate the association between negative spouse behaviors and depressive symptoms in a chronic pain sample.  Pain Med. 2000;  1 35-43
• 22 Newton-John T RO, Williams A C. Solicitousness revisited: a qualitative analysis of spousal responses to pain behaviors. In: Devor M, Rowbotham M, Weisenfield-Hallin Z Proceedings of the 9th World Conference on Pain. Progress in Pain Research and Management, Vol 16. Seattle; IASP Press 2000: 1113-1122
• 23 Keefe F J, Bradley L A, Main C J. Psychological assessment of the pain patient for the general clinician. In: Max M Pain 1999-An Updated Review. Seattle; IASP Press 1999: 219-230
• 24 Osterwiess M, Kleinman A, Mechanic D Committee on Pain Disability and Chronic Illness Behavior. Pain Disability: Clinical, Behavioral and Public Policy Perspectives. Washington, DC; National Academy Press 1987
• 25 Steig R L. Roadblocks to effective pain management.  Med Clin North Am. 1999;  83 809-821
• 26 Fishbain D A. Current research on chronic pain and suicide.  Am J Public Health. 1996;  86 1320-1321
• 27 Fishbain D A, Cutler R B, Rosomoff H L, Steele-Rosomoff R. Risk for violent behavior in patients with chronic pain: evaluation and management in the pain facility setting.  Pain Med. 2000;  1 140-155
• 28 Gallagher R M, Rauh V, Haugh L et al.. Determinants of return to work in low back pain.  Pain. 1989;  39 55-68
• 29 Gallagher R M. Secondary gain in pain medicine: let us stick with biobehavioral data.  Pain Forum. 1994;  3 274-278
• 30 Fishbain D. Secondary gain concept: definition problems and its abuse in medical practice.  Pain Forum. 1994;  3 264-273
• 31 Gallagher R M, Williams B, Skelly J et al.. Worker's compensation and return-to-work in low back pain.  Pain. 1995;  61 299-307
• 32 Gallagher R M. Outcomes and moral hazards in the medical culture of opioid phobia.  Clin J Pain. 1998;  14 185-186
• 33 Morris D B. An invisible history of pain: early 19th-century Britain and America.  Clin J Pain. 1998;  14 191-196
• 34 Groopman J. Knife in the back. The New Yorker April 2002: 68-73
• 35 Gallagher R M. The pain decade and the public health.  Pain Med. 2000;  1 283-285
• 36 Gallagher R M. Chronic pain: a public health problem?.  Clin J Pain. 1998;  14 277-279
• 37 Gallagher R M, Verma S. Treatment and rehabilitation of chronic orthopedic pain syndromes. In: Stoudemire A, Fogel B, Greenblatt D Psychiatric Care of the Medical Patient. New York; Oxford 2000: 227-252
• 38 Gallagher R M, Verma S, Mossey J. Sources of late-life pain and risk factors for disability.  Geriatrics. 2000;  55 40-48
• 39 Mossey J, Gallagher R M, Tirumalasetti F. The effects of pain and depression on physical functioning in elderly residents of a continuing care retirement community residents: implications for health management.  Pain Med. 2000;  1 340-350
• 40 Gallagher R M, Mossey J. Inadequate pain care for elders: the need for a primary care-pain medicine community collaboration.  Pain Med. 2002;  3 180
• 41 Mossey J, Gallagher R M. A 2-year, prospective study of the effects of depression and pain on physical functioning and healthcare utilization in elderly persons in a retirement community.  Pain Med. 2004;  , In press
• 42 Fishbain D A. Approaches to treatment decisions for psychiatric comorbidity in the management of chronic pain patient.  Med Clin North Am. 1999;  83 737-760
• 43 King S A. Review: DSM-IV and pain.  Clin J Pain. 1995;  11 171-176
• 44 Beck A T, Steer R A, Garbin M G. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation.  Clin Psychol Rev. 1988;  8 77-100
• 45 Bruns D, Disorbio J M, Copeland-Disorbio J. Manual for the Battery for Health Improvement. Minnetonka, MN; NCS Assessments 1996
• 46 Atkinson J H, Slater M A, Patterson T L, Grant I, Garfin S R. Prevalence, onset, and risk of psychiatric disorders in men with chronic low back pain: a controlled study.  Pain. 1991;  45 111-121
• 47 Gallagher R M, Moore P, Chernoff I. The reliability of depression diagnosis in chronic low back pain: a pilot study.  Gen Hosp Psychiatry. 1995;  17 399-413
• 48 Ware J E, Sherbourne C D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.  Med Care. 1992;  30 473-483
• 49 Rogers W, Wittink H M, Wagner A, Cynn D, Carr D. Assessing individual outcomes during outpatient, multidisciplinary chronic pain treatment by means of an augmented SF-36.  Pain Med. 2000;  1 44-54
• 50 Rogers W, Wittink H M, Ashburn M, Cynn D, Carr D. Using the “TOPS”, an outcomes instrument for multidisciplinary outpatient pain treatment.  Pain Med. 2000;  1 55-67
• 51 Gallagher R M. The AAPM Uniform Outcomes Measures Project: report of the scientific advisory committee.  Pain Med Network. 1998;  13 5-6
• 52 Gallagher R M, Moree L, Mody S, Dodd S, Mossey J. Quality of life (SF-36) for patients with lower back diagnosis associated with chronic pain.  Pain Med. 2000;  1 204-205
• 53 Verma S, Gallagher R M. The psychopharmacologic treatment of depression and anxiety in the context of chronic pain.  Curr Pain Headache Rep. 2002;  6 30-39
• 54 Kroenke K, Price R K. Symptoms in the community: prevalence, classification, and psychiatric comorbidity.  Arch Intern Med. 1993;  153 2474-2480
• 55 American Academy of Pain Medicine and the American Pain Society .Consensus Statement on the Use of Opioids in Chronic Non-malignant Pain. Evansville, IL; American Academy of Pain Medicine 1996
• 56 American Academy of Pain Medicine, the American Pain Society and the Academy of Addiction Disorders .Definitions of Addiction, Tolerance and Physical Dependency. Evansville, IL; American Academy of Pain Medicine 2000
• 57 Mulrow C D, Williams Jr J W, Chiquette E et al.. Efficacy of newer medications for treating depression in primary care patients.  Am J Med. 2000;  108 54-64
• 58 Schulberg H C, Katon W, Simon G E, Rush A J. Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research practice guidelines.  Arch Gen Psychiatry. 1998;  55 1121-1127
• 59 Thase M E, Entsuah A R, Rudolph R L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.  Br J Psychiatry. 2001;  178 234-241
• 60 Danish University Antidepressant Group . Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study.  J Affect Disord. 1993;  28 105-116
• 61 Detke M J, Lu Y, Goldstein D J, Hayes J R, Demitrack M A. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.  J Clin Psychiatry. 2002;  63 308-315
• 62 Depression Guideline Panel .Depression in primary care. Clinical Practice Guideline, No 5. Rockville, MD; Agency for Health Care Policy and Research April 1993
• 63 Beasley Jr C M, Dornseif B E, Pultz J A, Bosomworth J C, Sayler M E. Fluoxetine versus trazodone: efficacy and activating-sedating effects.  J Clin Psychiatry. 1991;  52 294-299
• 64 Tollefson G D, Holman S L, Sayler M E, Potvin J H. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.  J Clin Psychiatry. 1994;  55 50-59
• 65 Simon G E, Heiligenstein J H, Grothaus L, Katon W, Revicki D. Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine.  J Clin Psychiatry. 1998;  59 49-55
• 66 Jick S S, Dean A D, Jick H. Antidepressants and suicide.  BMJ. 1995;  310 215-218
• 67 Simon G E, Heiligenstein J, Revicki D et al.. Long-term outcomes of initial antidepressant drug choice in a “real world” randomized trial.  Arch Fam Med. 1999;  8 319-325
• 68 Sawynok J, Esser M J, Reid A R. Antidepressants as analgesics: an overview of central and peripheral mechanisms of action.  J Psychiatry Neurosci. 2001;  26 21-29
• 69 Speigel K, Kalb R, Pasternak G W. Analgesic activity of tricyclic antidepressants.  Ann Neurol. 1983;  13 462-465
• 70 Sierralta F, Pinardi G, Miranda H F. Effects of p-chlorophenylalanine and alpha-methyltyrosine on the antinociceptive effect of antidepressant drugs.  Pharmacol Toxicol. 1995;  77 276-280
• 71 Schreiber S, Backer M M, Weizaman R, Pick G G. The antinociceptive effects of fluoxetine.  Pain Clin. 1996;  9 349-356
• 72 Hwang A S, Wilcox G L. Analgesic properties of intrathecally administered heterocyclics.  Pain. 1987;  28 343-355
• 73 Iwashita T, Shimizu T. Imipramine inhibits intrathecal substance P-induced behaviour and blocks spinal cord substance P receptors in mice.  Brain Res. 1992;  581 59-66
• 74 Eisenach J C, Gebhart G F. Intrathecal amitriptyline acts as a N-methyl-D-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats.  Anesthesiology. 1995;  83 1046-1054
• 75 Sawynok J, Esser M J, Reid A R. Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat.  Pain. 1999;  82 149-158
• 76 Sawynok J, Reid A R, Esser M J. Peripheral antinociceptive action of amitriptyline in the rat formalin test: involvement of adenosine.  Pain. 1999;  80 45-55
• 77 Scott M A, Letrent K J, Hager K L, Burch J L. Use of transdermal amitriptyline gel in a patient with chronic pain and depression.  Pharmacotherapy. 1999;  19 236-239
• 78 Fishbain D A, Cutler R, Rosomoff H L, Rosomoff R S. Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review.  Pain Med. 2000;  1 310-316
• 79 Max M. Antidepressants as Analgesics. Progress in Pain Research and Management. Vol 1. Seattle; IASP Press 1994
• 80 Blumer D, Heilbron M. Chronic pain as a variant of depressive disease-the pain-prone disorder.  J Nerv Ment Dis. 1982;  170 381-406
• 81 Banks S M, Kerns R D. Explaining high rates of depression in chronic pain: a diathesis-stress framework.  Psychol Bull. 1996;  119 95-110
• 82 Sasson Y, Zohar J, Chopra M et al.. Epidemiology of obsessive-compulsive disorder: a world view.  J Clin Psychiatry. 1997;  58(suppl 12) 7-10
• 83 Kuch K, Cox B J, Evans R J. Posttraumatic stress disorder and motor vehicle accidents: a multidisciplinary overview.  Can J Psychiatry. 1996;  41 429-434
• 84 American Psychiatric Association .Practice guidelines for the treatment of patients with panic disorder. In: Practice Guidelines for the Treatment of Psychiatric Disorders. Washington, DC; APA 2002: 635-696
• 85 Merritt T C. Recognition and acute management of patients with panic attacks in the emergency department.  Emerg Med Clin North Am. 2000;  18 289-300
• 86 Sheehan D V. The management of panic disorder.  J Clin Psychiatry. 2002;  63(suppl 14) 17-21
• 87 Davidson J RT, Kudler H S, Smith R D et al.. Treatment of posttraumatic stress disorder with amitriptyline and placebo.  Arch Gen Psychiatry. 1990;  47 259-266
• 88 Kosten T R, Frank J B, Dan E, McDougle C J, Giller Jr E L. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine.  J Nerv Ment Dis. 1991;  179 366-370
• 89 van der Kolk B A, Dreyfuss D, Michaels M. Fluoxetine in posttraumatic stress disorder.  J Clin Psychiatry. 1994;  55 517-522
• 90 Connor K M, Sutherland S M, Tupler L A et al.. Fluoxetine in post-traumatic stress disorder: randomized double-blind study.  Br J Psychiatry. 1999;  175 17-22
• 91 Brady K T, Pearlstein T, Asnis G M et al.. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial.  JAMA. 2000;  283 1837-1844
• 92 Davidson J RT, Rothbaum B O, van der Kolk B A, Sikes C R, Farfel G M. Multicenter, double-blind comparisons of sertraline and placebo in the treatment of posttraumatic stress disorder.  Arch Gen Psychiatry. 2001;  58 485-492
• 93 Marshall R D, Schneier F R, Fallon B A et al.. An open trial of paroxetine in patients with non-combat-related, chronic posttraumatic stress disorder.  J Clin Psychopharmacol. 1998;  18 10-18
• 94 Seedat S, Stein D J, Emsley R A. Open trial of citalopram in adults with post-traumatic stress disorder.  Int J Neuropsychopharmacol. 2000;  3 135-140
• 95 Davidson J RT, Weisler R H, Malik M L, Tupler L A. Fluvoxamine in civilians with posttraumatic stress disorder.  J Clin Psychopharmacol. 1998;  18 93-95
• 96 Hidalgo R B, Hertzberg M A, Mellman T A et al.. Nefazodone in post-traumatic stress disorder: results from six open-label trials.  Int Clin Psychopharmacol. 1999;  14 61-68
• 97 Canive J M, Clark R D, Calaris L A, Quails C, Tuason V B. Bupropion treatment in veterans with posttraumatic stress disorder: an open study.  J Clin Psychopharmacol. 1998;  18 379-383
• 98 Connor K M, Davidson J RT, Weisler A H, Ahearn E P. A pilot study of mirtazapine in post-traumatic stress disorder.  Int Clin Psychopharmacol. 1999;  14 29-31
• 99 Kirkwood C K, Hayes P E. Anxiety disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM Pharmacotherapy. 3rd ed. Stamford, CT; Appleton & Lange 1997: 1443-1462
• 100 Rocca P, Fonzo V, Scotta M, Zanalda E, Ravissa L. Paroxetine efficacy in the treatment of generalized anxiety disorder.  Acta Psychiatr Scand. 1997;  95 444-450
• 101 Hedges D W, Reimherr F W, Strong R E, Halls C H, Rust C. An open trial of nefazodone in adult patients with generalized anxiety disorder.  Psychopharmacol Bull. 1996;  32 671-676
• 102 Hoehn-Saric R, McLeod D R, Zimmerli W D. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms.  J Clin Psychiatry. 1988;  49 293-301
• 103 Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam.  Arch Gen Psychiatry. 1993;  50 884-895
• 104 Kahn R J, McNair D M, Lipman R S et al.. Imipramine and chlordiazepoxide in depressive and anxiety disorders, II: efficacy in anxious outpatients.  Arch Gen Psychiatry. 1986;  43 79-85
• 105 Davidson J R, DuPont R L, Hedges D, Haskins J T. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.  J Clin Psychiatry. 1999;  60 528-535
• 106 Rickels K, Pollack M H, Sheehan D V, Haskins J T. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.  Am J Psychiatry. 2000;  157 968-974
• 107 Gallagher R M, Pasol E. Psychopharmacologic drugs in the chronic pain syndromes.  Curr Rev Pain. 1997;  1 138-152
• 108 Krames E S. Interventional pain management: appropriate when less invasive therapies fail to provide adequate analgesia.  Med Clin North Am. 1999;  83 787-808
• 109 Caudill M, Schnable R, Zuttermeister P, Benson H, Friedman R. Decreased clinic utilization by chronic pain patients: response to behavioral medicine intervention.  Clin J Pain. 1991;  7 305-310
• 110 Gallagher R M, McCann W J, Jerman A, Hughes J, Langelier R, Stewart F. The behavioral medicine service-an administrative model for biopsychosocial medical care, teaching and research.  Gen Hosp Psychiatry. 1990;  12 283-295
• 111 Caudill M A. Managing Pain Before It Manages You. New York; Guilford Press 1995
• 112 Gazda T, Gallagher R M, Little D N, Sproul M S. The practice group seminar-a Balint-type group in a family practice setting.  Fam Med. 1984;  16 54-58
• 113 Langelier R P, Gallagher R M. Outpatient treatment of chronic pain groups for couples.  Clin J Pain. 1989;  5 227-231
• 114 Weisberg J, Keefe F. Personality disorders in the chronic pain population.  Pain Forum. 1997;  6 1-9